Recent Press Releases

FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for patients with Waldenström's macroglobulinemia (WM), a rare form of cancer that begins in the...

Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)

01/29/2015 LAVAL, Quebec, Jan. 29, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into a "stalking horse"...

VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity

VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual...

AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results

AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results - Reports Full-Year Adjusted EPS of $3.32, Up 5.7 Percent; GAAP EPS $1.10 - Delivers Fourth-Quarter Adjusted Revenue of $5.371...

Lilly Reports Fourth-Quarter and Full-Year 2014 Results, Updates 2015 Guidance

INDIANAPOLIS, Jan. 30, 2015 /PRNewswire/ -- Fourth-quarter 2014 revenue declined 12 percent driven by the impact of U.S. patent expirations for Cymbalta and Evista and the unfavorable impact of...

Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH™ Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia

FIND FH Initiative Unites Industry, Advocacy Community and Academia in an Effort to Support People Affected by Familial Hypercholesterolemia (FH), a Serious Genetic Disorder

Abbott Reports Fourth-Quarter 2014 Results

- Fourth-Quarter EPS Above Previous Guidance Range, Including Results From Discontinued Operations -

ABBOTT PARK, Ill., Jan.

Celgene Reports Fourth Quarter and Full Year 2014 Operating and Financial Results

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported operating results for the fourth quarter and full year of 2014. For the fourth quarter of 2014, net product sales were...

AMERICANS FACED DOUBLE DIGIT INCREASES IN PRESCRIPTION DRUG PRICES IN 2014, ACCORDING TO TRUVERIS NATIONAL DRUG INDEX SM

AMERICANS FACED DOUBLE DIGIT INCREASES IN PRESCRIPTION DRUG PRICES IN 2014, ACCORDING TO TRUVERIS NATIONAL DRUG INDEX SM Branded Drugs Jump 15%, Specialty Drugs Rise 10%, Generics Up 5% NEW...

Salix Provides Update on Audit Committee Review

Audit Committee Determines to Restate Financial Statements for FY2013 and First Three Quarters of 2014 *Aggregate impact of errors on net product revenue and net income over all previously...

Statement by United States Trade Representative Michael Froman at the House Ways and Means Committee

"Thank you, Chairman Ryan, Ranking Member Levin, Members of the House Ways and Means Committee, thanks for the opportunity to testify on the President's trade agenda. I will try to keep this short to...

Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70

THOUSAND OAKS, Calif., Jan. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2014. Key results include: For the fourth quarter,...

Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myelom

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Jan. 27, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the submission of a...

Roche delivers solid results in 2014

• Group sales up 5% at constant exchange rates , 1% in Swiss francs • Pharmaceuticals Division sales up 4%, driven by oncology (HER2-positive breast cancer medicines, Avastin) and strong...

Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results

Achieves Accelerated U.S. Regulatory Approval for Opdivo in Metastatic Melanoma Announces Early Stop of CheckMate -017, a Phase 3 Study of Opdivo, After Data Demonstrates Superior...

HealthWarehouse.com Responds to Senator Klobuchar & McCain On Reintroduction of Canadian Pharmacy Bill

HealthWarehouse.com Responds to Senator Klobuchar & McCain On Reintroduction of Canadian Pharmacy Bill

<0> HealthWarehouse.comLalit Dhadphale, 859-444-7341 </0>

Alimera Sciences' ILUVIEN® Receives Marketing Authorization in Finland and Luxembourg

ATLANTA, Jan. 26, 2015 /PRNewswire/ -- Alimera Sciences, Inc.

GSK expands its portfolio of medicines in the US for patients with asthma and COPD

Arnuity™ Ellipta® now available in the US for once-daily treatment of asthma.

World OTC Pharmaceuticals Market Forecast 2015-2025

LONDON, January 26, 2015 /PRNewswire/ --

Prospects for Leading Companies